Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 3, 1997

View Archived Issues

Interim phase III results reported for BCX-34

Sugen's angiogenesis inhibitor SU-5416 enters phase I

Genelabs Technologies reports phase III results from SLE trial

Cypros to start phase III trial for CABG

BioTime completes phase III trial with blood volume plasma extender

First long-term data for indinavir reported at ICAAC

Aastrom: Q4 and fiscal 1997 highlights

Techniclone: Q1 1997 highlights

Cortex: Q4 and fiscal 1997 highlights

Wakunaga prepares acidic fluoroquinolone

Novel antibacterial agents that inhibit bacterial two-component systems

R.W. Johnson identifies TCS inhibitor with potent antibacterial activity

Microcide identifies cephalosporin with excellent Gram-positive activity

Korean researchers present novel 3-isoxazolylvinylcephalosporins

Intracavernous moxisylyte recommended for first-line treatment of ED

OraVax to market and distribute Evans Medical's yellow fever vaccine

Effects of BQ-123 and BQ-788 on ET-1-induced corpus cavernosum contractions

Wyeth-Ayerst to promote Immunex's ENBREL in U.S.

L-Arginine not associated with objective improvement in organic ED

Linsidomine + moxisylyte for ED

ChemTrak reacquires rights to H. pylori test

Femara launched in U.S.

Regeneron and P&G joint development program for obesity

BioQuest acquires ICC

Abbott receives FDA clearance to market Gabitril

Neutralase proceeds to phase III trials

FDA clears Serevent Diskus

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...